L&C Bio Secures World’s First NMPA Approval for ‘MegaDerm Plus’ in China
L&C Bio (CEOHwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, “MegaDerm Plus.” This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales […]